| Product Code: ETC9945141 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The United Kingdom (UK) gastritis market is a significant segment within the country`s healthcare industry, characterized by a high prevalence of the condition and a variety of treatment options. Gastritis, the inflammation of the stomach lining, affects a considerable portion of the population in the UK, leading to symptoms such as stomach pain, bloating, nausea, and vomiting. The market is driven by the increasing awareness about gastrointestinal health, lifestyle factors such as unhealthy diet and stress, and the rising geriatric population. Key players in the market offer various treatment options including medications, lifestyle modifications, and dietary changes to manage and alleviate gastritis symptoms. As the healthcare sector in the UK continues to evolve, advancements in treatment options and a growing focus on preventive healthcare are expected to further drive the gastritis market in the country.
The United Kingdom (UK) gastritis market is witnessing a growing demand for over-the-counter (OTC) medications and natural remedies due to the increasing awareness of digestive health among the population. Proton pump inhibitors (PPIs) are the most commonly prescribed medication for gastritis, but there is a rising trend towards natural supplements like probiotics and herbal remedies for managing gastritis symptoms. The market also offers opportunities for pharmaceutical companies to develop innovative treatment options with fewer side effects and better efficacy. Additionally, the growing prevalence of Helicobacter pylori infection, which is a major cause of gastritis, presents an opportunity for diagnostic companies to develop advanced testing methods. Overall, the UK gastritis market is evolving towards a more holistic approach to managing the condition, providing opportunities for both pharmaceutical and alternative medicine sectors to cater to the diverse needs of consumers.
In the United Kingdom`s gastritis market, challenges include increasing prevalence of gastritis due to factors such as unhealthy dietary habits, alcohol consumption, and stress. The rise in antibiotic resistance poses a threat to the effectiveness of Helicobacter pylori eradication therapy, a common treatment for gastritis. Additionally, the availability of over-the-counter medications for symptom relief may lead to self-medication practices, potentially delaying proper diagnosis and treatment by healthcare professionals. Economic pressures on the healthcare system could also impact access to specialized care for gastritis patients. Furthermore, educating the population about the importance of early detection and management of gastritis remains a challenge in improving overall outcomes and reducing the burden of this gastrointestinal condition in the UK.
The United Kingdom Gastritis Market is primarily driven by factors such as increasing prevalence of gastritis due to lifestyle changes, rising consumption of alcohol and tobacco, and a growing elderly population prone to gastrointestinal issues. Additionally, the growing awareness about gastrointestinal health and the availability of advanced diagnostic and treatment options are contributing to the market growth. The rise in healthcare expenditure, ongoing research and development activities for innovative therapies, and the high prevalence of Helicobacter pylori infection in the UK population are also key drivers influencing the gastritis market in the country. Furthermore, the increasing adoption of over-the-counter medications and rising demand for effective treatment options are expected to fuel market expansion in the forecast period.
Government policies related to the UK Gastritis Market primarily focus on regulating the marketing, sales, and distribution of gastritis medications and treatments to ensure patient safety and efficacy. The Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and monitoring of gastritis medicines, ensuring they meet required standards. Additionally, the National Institute for Health and Care Excellence (NICE) evaluates the cost-effectiveness of treatments and provides guidelines for healthcare professionals to follow in managing gastritis. The government also promotes initiatives to raise awareness about gastritis prevention and treatment options among the public and healthcare providers. Overall, government policies in the UK Gastritis Market aim to facilitate access to safe and effective treatments while controlling healthcare costs and improving patient outcomes.
The United Kingdom (UK) gastritis market is expected to witness steady growth in the coming years due to the increasing prevalence of gastritis among the population, primarily driven by factors such as unhealthy dietary habits, high alcohol consumption, and rising stress levels. The market is also anticipated to benefit from advancements in diagnostic technologies and treatment options, leading to improved patient outcomes and quality of care. Additionally, the growing awareness about gastrointestinal health and the importance of early detection and treatment of gastritis is likely to further propel market growth. Overall, the UK gastritis market is projected to expand as healthcare providers focus on delivering effective and personalized treatments to address the rising burden of gastritis in the country.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) Gastritis Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) Gastritis Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) Gastritis Market - Industry Life Cycle |
3.4 United Kingdom (UK) Gastritis Market - Porter's Five Forces |
3.5 United Kingdom (UK) Gastritis Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.6 United Kingdom (UK) Gastritis Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.7 United Kingdom (UK) Gastritis Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 United Kingdom (UK) Gastritis Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 United Kingdom (UK) Gastritis Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United Kingdom (UK) Gastritis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of gastritis in the UK population |
4.2.2 Growing awareness about gastrointestinal health and related conditions |
4.2.3 Adoption of unhealthy dietary habits leading to higher cases of gastritis |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for gastritis treatment and medications |
4.3.2 High cost associated with advanced treatment options for gastritis |
4.3.3 Increasing competition from alternative therapies and natural remedies |
5 United Kingdom (UK) Gastritis Market Trends |
6 United Kingdom (UK) Gastritis Market, By Types |
6.1 United Kingdom (UK) Gastritis Market, By Treatment |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) Gastritis Market Revenues & Volume, By Treatment, 2021- 2031F |
6.1.3 United Kingdom (UK) Gastritis Market Revenues & Volume, By Acid Blocking Medications, 2021- 2031F |
6.1.4 United Kingdom (UK) Gastritis Market Revenues & Volume, By Prevacid 24HR (lansoprazole), 2021- 2031F |
6.1.5 United Kingdom (UK) Gastritis Market Revenues & Volume, By Nexium 24HR, 2021- 2031F |
6.1.6 United Kingdom (UK) Gastritis Market Revenues & Volume, By Acid Reducing Medications, 2021- 2031F |
6.1.7 United Kingdom (UK) Gastritis Market Revenues & Volume, By Nexium, 2021- 2031F |
6.1.8 United Kingdom (UK) Gastritis Market Revenues & Volume, By Prevacid, 2021- 2031F |
6.1.9 United Kingdom (UK) Gastritis Market Revenues & Volume, By Others, 2021- 2031F |
6.1.10 United Kingdom (UK) Gastritis Market Revenues & Volume, By Others, 2021- 2031F |
6.2 United Kingdom (UK) Gastritis Market, By Type |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) Gastritis Market Revenues & Volume, By Acute Gastritis, 2021- 2031F |
6.2.3 United Kingdom (UK) Gastritis Market Revenues & Volume, By Chronic Gastritis, 2021- 2031F |
6.2.4 United Kingdom (UK) Gastritis Market Revenues & Volume, By Erosive Gastritis, 2021- 2031F |
6.2.5 United Kingdom (UK) Gastritis Market Revenues & Volume, By Non-Erosive Gastritis, 2021- 2031F |
6.3 United Kingdom (UK) Gastritis Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 United Kingdom (UK) Gastritis Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 United Kingdom (UK) Gastritis Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.4 United Kingdom (UK) Gastritis Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 United Kingdom (UK) Gastritis Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United Kingdom (UK) Gastritis Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 United Kingdom (UK) Gastritis Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.5 United Kingdom (UK) Gastritis Market Revenues & Volume, By Others, 2021- 2031F |
6.5 United Kingdom (UK) Gastritis Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 United Kingdom (UK) Gastritis Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 United Kingdom (UK) Gastritis Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 United Kingdom (UK) Gastritis Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
6.5.5 United Kingdom (UK) Gastritis Market Revenues & Volume, By Others, 2021- 2031F |
7 United Kingdom (UK) Gastritis Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) Gastritis Market Export to Major Countries |
7.2 United Kingdom (UK) Gastritis Market Imports from Major Countries |
8 United Kingdom (UK) Gastritis Market Key Performance Indicators |
8.1 Number of diagnosed cases of gastritis in the UK |
8.2 Rate of prescription of gastritis medications by healthcare providers |
8.3 Patient adherence to treatment plans and follow-up appointments |
9 United Kingdom (UK) Gastritis Market - Opportunity Assessment |
9.1 United Kingdom (UK) Gastritis Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.2 United Kingdom (UK) Gastritis Market Opportunity Assessment, By Type, 2021 & 2031F |
9.3 United Kingdom (UK) Gastritis Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 United Kingdom (UK) Gastritis Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 United Kingdom (UK) Gastritis Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United Kingdom (UK) Gastritis Market - Competitive Landscape |
10.1 United Kingdom (UK) Gastritis Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) Gastritis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |